Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Asia. The aim of this trial is to investigate pharmacokinetics of insulin detemir in healthy Taiwanese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Considered generally healthy upon completion of medical history and physical examination as judged by the investigator

• Body mass index (BMI) between 18 and 27 kg/m^2, inclusive

• Fasting plasma glucose maximum 6.1 mmol/l

• Non-smoker or smoking maximum 5 cigarettes per day or the equivalent

Exclusion Criteria:

• Participation in any other clinical trial involving other investigational products within the last 3 months

• Subject with a history of alcohol or drug dependence

• Subject with a first-degree relative with diabetes mellitus